The earnings call highlighted strong revenue growth, particularly in the Greenbrook clinics, and significant progress towards cash flow positivity. However, challenges such as a decline in gross margin, increased operating expenses, and ongoing difficulties with the SPRAVATO buy and bill model were also noted.

Company Guidance -

Q3 2025

In the recent call, Neuronetics provided a comprehensive financial and operational update for the second quarter of 2025. The company reported total revenue of $38.1 million, marking an 18% year-over-year increase on an adjusted pro forma basis. Notably, revenue from the NeuroStar business reached $15.1 million, including $3.5 million from NeuroStar system revenue with 41 systems shipped, and a U.S. treatment session revenue of $10.8 million, which grew by 13% on a pro forma basis. U.S. clinic revenue stood at a record $23 million. The company made substantial progress towards cash flow positivity, with cash used in operations at $3.5 million, better than the guided target of under $5 million. Neuronetics outlined three strategic priorities: executing the Greenbrook growth strategy, scaling the Better Me Provider (BMP) Program, and enhancing operational efficiencies. The Greenbrook integration yielded positive results, with the strongest clinic revenue quarter to date. The company also focused on optimizing cash collections and reported improvements in claims processing and reimbursement timing for its SPRAVATO rollout. Neuronetics maintained full-year revenue guidance between $149 million and $155 million, with gross margin expectations adjusted to 48%-50% due to revenue mix shifts. The operational momentum and strategic initiatives underscore Neuronetics' confidence in achieving cash flow positivity by the fourth quarter of 2025.

Strong Revenue Growth

Total revenue was $38.1 million for Q2 2025, an 18% year-over-year increase on an adjusted pro forma basis. This includes $15.1 million from the NeuroStar business and $23 million in U.S. clinic revenue, marking the largest quarterly clinic revenue to date.

Progress Toward Cash Flow Positivity

Cash used in operations was $3.5 million, better than the previously guided target of under $5 million and a significant improvement from the first quarter.

Greenbrook Growth Strategy Success

The Greenbrook growth strategy continues to exceed expectations with improved patient conversion rates and strong results from the RAM program, leading to the strongest Greenbrook clinic revenue quarter in the history of the business.

Adolescent Treatment Growth

25% growth in adolescent new patient starts in H1 2025 compared to 2024, with a 2.6x increase among 15- to 17-year-olds.

SPRAVATO Rollout Momentum

77 of 83 SPRAVATO-eligible clinics now offer the therapy, up from 75 in Q1, with a full rollout expected by year-end.

Neuronetics (STIM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

STIM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.13 / -	-0.44	―	―	―
Aug 05, 2025	2025 (Q2)	-0.08 / -0.15	-0.33	54.55% (+0.18)
May 06, 2025	2025 (Q1)	-0.12 / -0.21	-0.27	22.22% (+0.06)
Mar 04, 2025	2024 (Q4)	-0.24 / -0.33	-0.19	-73.68% (-0.14)
Nov 12, 2024	2024 (Q3)	-0.23 / -0.44	-0.33	-33.33% (-0.11)
Aug 12, 2024	2024 (Q2)	-0.27 / -0.33	-0.17	-94.12% (-0.16)
May 07, 2024	2024 (Q1)	-0.31 / -0.27	-0.38	28.95% (+0.11)	―
Mar 05, 2024	2023 (Q4)	-0.26 / -0.19	-0.3	36.67% (+0.11)	―
Nov 07, 2023	2023 (Q3)	-0.31 / -0.33	-0.28	-17.86% (-0.05)	―
Aug 08, 2023	2023 (Q2)	-0.35 / -0.17	-0.39	56.41% (+0.22)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

STIM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$4.66	$4.54	-2.58%
May 06, 2025	$4.50	$4.50	0.00%
Mar 04, 2025	$4.26	$5.06	+18.78%
Nov 12, 2024	$1.10	$0.69	-37.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neuronetics Inc (STIM) report earnings?

Neuronetics Inc (STIM) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).

What is Neuronetics Inc (STIM) earnings time?

Neuronetics Inc (STIM) earnings time is at Nov 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is STIM EPS forecast?

STIM EPS forecast for the fiscal quarter 2025 (Q3) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing